

People

Robert A.D. Scott joins Atherogenics

Atherogenics, a pharmaceutical company that focuses on the discovery and development of drugs for chronic inflammatory diseases (<http://www.atherogenics.com>), has announced the appointment of Robert A.D. Scott as Senior Vice President of Clinical Development and Regulatory Affairs. Scott will also serve as the company's Chief Medical Officer and a member of the Company's Executive Committee.

Scott joins Atherogenics from his position as Vice President at Pfizer Pharmaceutical group, where he was Worldwide Medical Therapeutic Head, responsible for leading its cardiovascular and metabolic group. His career at Pfizer spanned more than a decade and included responsibility for the development of world-leading pharmaceuticals, such as Lipitor®, Norvasc® and the diabetes products, Glucotrol XL® and Exubera®. During his time at Pfizer, Scott also held the position of Medical Director for Pfizer's Cardiovascular Risk Factors Group and Senior Associate Medical Director for Pfizer's Calcium Channel Blocker Team and Medical Director of Pfizer South Africa.

Russell Medford, President and Chief Executive Officer of Atherogenics, said: '[Scott's] proven clinical development and regulatory leadership abilities coupled with his expertise in the global cardiovascular industry add tremendous value to our company.'

New VP of R&D for Metaprobe

William C. Dow has been appointed as Vice President of R&D at Metaprobe (<http://www.metaprobe.com>). Metaprobe is a privately held biopharmaceutical company that develops novel functional imaging agents for magnetic resonance imaging (MRI).

Dow joins the company from Pharmacyclics, where he held several senior management positions, including Vice President, then Senior Director of chemical R&D; before this, he was Director of Chemical Development and Manufacturing at Nycomed Salutar. Dow has also held research positions at Syntex research and Eli Lilly and Co. More recently he was a chemical and pharmaceutical

consultant providing R&D start-up expertise to biopharmaceutical companies.

Michael Beeuwsaert, President and CEO at Metaprobe said: 'Dr Dow's demonstrated expertise in successfully advancing candidates through the drug development process will be valuable to MetaProbe as we work to develop novel agents that will add breakthrough capabilities to traditional imaging techniques, such as MRI.'

Human Genome Sciences appoint new VP of Process Development

Human Genome Sciences (<http://www.hgsi.com>) has announced the appointment of Daniel Gold as Senior Vice President of Process Development. Gold joins the company from his position as Vice President, Process Development and Chief Operating Officer at Diosynth-RTP, a contract biopharmaceutical process development and manufacturing division of Akzo Nobel.

Since 1996, at Diosynth-RTP, Gold has led the development of manufacturing processes for fifteen different protein therapeutics, as well as being responsible for analytical requirement for NDA and licensing applications. Gold brings nearly 20 years of biopharmaceutical process development and marketing experience to Human Genome Sciences. He began his career as a process development scientist with Synergen and has since held senior positions at several biopharmaceutical companies, including Genecor, Genetech and Lkhepri Pharmaceuticals.

William A. Haseltine, Chairman and Chief Executive Officer at Human Genome Sciences commented: 'Dan Gold brings extensive experience in designing and leading team-based approaches to the rapid development of therapeutic proteins as pharmaceutical products. I am pleased to welcome Dan to the Human Genome Sciences team.'

TolerRx appoints new VP and Head of Clinical Development and Medical Affairs

TolerRx (<http://www.tolerrx.com>) has announced the appointment of Louis Vaickus as Vice President and Head of Clinical Developments and Medical Affairs.

Vaickus joins TolerRx from Sepracor, where he was Senior VP of Medical Affairs.

He joined Sepracor in 1998 as VP of Clinical Research, where he supervised Phase I-IV trials, regulatory approval submissions, medical marketing and clinical publications for several products, including Xopenex® and Estorra®.

Douglas J. Ringler, President and CEO of TolerRx, said: 'Dr Vaickus has over 25 years experience in the preclinical, clinical and post-marketing research and development of biologics and small molecules as a research scientist, academic physician and pharmaceutical executive. We are very pleased to have such a highly respected clinician leading TolerRx's medical program as we advance our two lead products through clinical assessment, development and commercialization.'

TolerRx is a biopharmaceutical company specializing in the discovery and development of therapies that induce, maintain or eliminate immunological tolerance and reprogram the immune system to treat immune-mediated disorders.

IBIO names President

The Illinois Biotechnology Industry Organization (IBIO) announced the appointment of David Miller as president of the association. Miller assumed his role as the first full-time executive in the history of the organization in September 2002.

Michael Hogg, chairman of IBIO, said: '[IBIO's] rapid growth in membership reflects the community's belief that we can build a world-class life sciences business centre... and we recruited an experienced business development executive to turn that vision into reality.'

Before joining IBIO, Miller held executive business development positions with high technology firms and his experience includes the planning and execution of major economic development initiatives while serving as the Mayor's aide for business development in Madison (WI, USA).

Miller commented that 'I envision IBIO acting as an organizer of the agenda and tireless agent of Illinois' becoming a supportive partner to major and growing life sciences companies.'

IBIO is the Illinois affiliate of the Washington DC-based Biotechnology Industry Organization.

People was written by
Joanna Owens and Joanne Clough